Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Protein structures are powerful tools in the development of medical drugs, but they are not very accessible to non-specialists. Research informatics presents these structures more simply and interactively, and helps scientists make decisions. This will hopefully accelerate the development of new medicines.

Q: Can you tell us a little bit about your research interests?

Brian Marsden: I work for an organisation called the Structural Genomics Consortium or SGC, which is interested in trying to solve the structures of human proteins and making them available to the public. One of the key things we are particularly interested in is understanding how these protein structures inform or create disease. As part of the work associated with that, we generate a lot of data. My research is interested in how we capture that data and be able to ask questions to better understand how these mutations for example in proteins may cause disease.

Q: How do you use an informatics approach to support the work done at the SGC?

BM: We have a very multidisciplinary team at the SGC: we have people who are doing cloning of genes for example, creating proteins, solving the structures of proteins, even people who are doing medicinal chemistry making small molecules to interrogate those proteins. One of the things we have to do is to capture this information in a way that makes sense and is easy to mine. As a consequence of that, at the SGC we are entirely paperless and that means that everything that we do is captured in electronic format. This means that we have access to information from 10 years or more, no matter whether people are still with us or not. One of the other really important aspects of being able to have everything paperless, or electronically, is that we have the ability to ask questions or spot trends in the work that we are doing, finding out about what we are doing right, what we are doing wrong and spotting things that we would not have seen otherwise.

Q: How can visualisation tools help with drug discovery?

BM: At the SGC we solve many protein structures of human proteins. These make very pretty pictures but they are not particularly accessible to those people who are not structural biologists. It is really important that we find ways to make this information available to those who do not understand how to interpret these structures. Something we have pioneered at the SGC over that last 10 years is the ability to show these protein structures in a context that makes sense to the scientist. For example, we can show protein structures in a web browser, directly connected with a narrative, in an interactive form. This means that people like medicinal chemists for example can now look at these protein structures and understand the context of what that actually means, and help them make decisions about what sort of compounds they make.

Q: What are the most important lines of research that have emerged in the last 5-10 years?

BM: When we started at the SGC over 10 years ago, the sequencing of the human genome was a really big thing and we expected that would be a big game changer in terms of what we do. I would say that the revolution hasn't happened as quickly as we would have expected but these days it is possible to sequence a human genome within a day or so for less than a $1,000. That means that you can now ask questions like "what exactly is a single cell doing on its own in an organism?" We can now understand the interplay between how cells in the pancreas for example, or in the brain may be working in respect to each other. No two single cells are the same, so this means that what those cells are doing may be very different.

We can also ask bigger questions, we can do something called metagenomics - this is the study where we look at environmental effects that may be occurring in a bacterial colony. A classic example may be the bacterial colony that you have in your gut. It has been found that the flora you have in the gut may actually influence whether you have irritable bowel disease for example. By sequencing all these bacteria we can have a better understanding how that interplay may occur within a disease.

Q: Why does this line of work matter and why should we fund it?

BM: Drug discovery is an incredibly expensive thing to do, and there are no guarantees that a drug that you think you have is going to work out. Something we want to do at the SGC is to find ways to find the diamonds in the rough effectively. What are the right targets? What are the right genes? What are the right proteins that we should be working on to get new medicines quicker, more cheaply and in a more relevant way?

Q: How does your work fit into translational medicine within the department?

BM: Recently at the SGC we have been awarded a large strategic award by the Wellcome Trust which is focused on us developing something called target enabling packages. These build upon the work we have done at the SGC for many years: protein structures, how to make proteins, what small molecules we should use etc., and packaging them up together into something which people within academia and industry can go away and use to better understand whether the protein associated with those packages are really the real deal in terms of drug discovery. What we hope is that therefore this will accelerate the translational aspect of the work that we are doing.

Brian Marsden

Research Informatics

Dr Brian Marsden heads the SGC Research Informatics group. He aims to make structural and chemical biology data accessible to non-experts, by providing computational resources including data management, sample tracking, in silico modelling support plus provision of public access to SGC data. His research is focussed upon novel visualisation tools and methodology for structural biology and drug discovery.

More podcasts related to Translational & Clinical

David Stuart: Structural biology and vaccines

The basis of an effective vaccine is that a pathogen is physically recognised by the immune system.

Kay Grunewald: Structural cell biology of virus infection

Understanding the entirety of a virus’ ‘life cycle’ requires an understanding of its transient structures at the molecular level. Using imaging techniques allows us to understand the communication between the virus and the components of the cell it is infecting, which can ultimately help to treat infectious diseases.

Jens Rittscher: Biological imaging

Video microscopy aims to improve target discovery and drug development and to do so generates large volumes of data. Fluorescence labelling helps make intrinsic cellular functions visible and computational tools then enable analysis of these data sets to improve our understanding of cellular functions.

Sebastian Nijman: Pharmacogenomics

In the context of cancer, genetic diversity means that we respond differently to various treatments. Pharmacogenomics sits at the intersection between genetics and drugs. Better understanding of the genetic landscape of cancer and the recent increase of targeted drugs allow us to better match patients with the best treatments, improving care.

Ian Pavord: Asthma

Ian Pavord's research in to airway inflammation has resulted in mepolizumab being identified as an effective inhibitor of eosinophilic inflammation and asthma attacks. Mepolizumab is currently in Phase III clinical trials and if found to be effective could be a promising treatment for certain asthma patients.

Trudie Lang: The Global Health Network

The Global Health Network is a successful and growing online science park comprised of varied research communities for different health research groups and cross-cutting health topics. It is built for the research and wider health community by researchers and public health practitioners themselves. It is a trusted source of quality information, education and research tools.

Najib Rahman: Respiratory Medicine

Respiratory medicine encompasses a large number of common diseases like pneumonia, asthma, emphysema and lung cancer. Outcomes are currently relatively poor and the area of research is underfunded. Recent progress have been made towards personalising treatment, and Dr Rahman's research aims at improving patient care.

Chris O’Callaghan: Atherosclerosis & immunity

Atherosclerosis is the most important cause of death worldwide. It is caused by the accumulation of both fatty material and immune cells. Over time, these set up an inflammatory reaction which causes a lot of damage to the blood vessel wall. Although we do have good therapies designed to lower the levels of fatty material, we haven’t any therapies specifically designed to target the effect of the immune system. Professor O'Callaghan's group is working towards developing such therapies.

Stefan Knapp: Development of chemical probes

While drugs were initially developped by testing natural products directly in humans, the current approach is to use chemical probes. These are small chemical coumpounds that inhibit selected targets, avoiding side effects. Professor Knapp produces structures of molecular targets and makes them widely available. This will allow a faster and more cost effective development of new drugs.

Translational Medicine

From Bench to Bedside

Ultimately, medical research must translate into improved treatments for patients. At the Nuffield Department of Medicine, our researchers collaborate to develop better health care, improved quality of life, and enhanced preventative measures for all patients. Our findings in the laboratory are translated into changes in clinical practice, from bench to bedside.